Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Deucravacitinib). Same strength and form. Confirm the switch with your doctor or pharmacist.
Indications & Uses
Tykin is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Recommended Evaluations and Immunizations Prior to Treatment Initiation: Evaluate patients for active and latent tuberculosis (TB) infection prior to initiating treatment with Deucravacitinib. If positive, start treatment for TB prior to Deucravacitinib.Recommended Dosage: The recommended dosage of Deucravacitinib is 6 mg taken orally once daily, with or without food. Do not crush, cut, or chew the tablets.Pediatric Use: The safety and effectiveness in pediatric patients have not been established.Geriatric Use: No overall differences in effectiveness have been observed between patients 65 years of age and older and younger adult patients.Recommended Dosage in Patients with Hepatic Impairment: Deucravacitinib is not recommended in patients with severe hepatic impairment (Child-Pugh C). No dosage adjustment is needed for patients with mild to moderate hepatic impairment.Renal Impairment: No dose adjustment is recommended in patients with mild, moderate, or severe renal impairment or in patients with end stage renal disease (ESRD) on dialysis.
Side Effects
The most common side effect of Deucrava include common cold, sore throat, and sinus infection (upper respiratory infections), cold sores (herpes simplex), sores on inner lips, gums, tongue, or roof of the mouth (canker sores), inflamed hair pores (folliculitis), acne. lt may cause serious allergic reactions including feeling faint or swelling in the face, eyelids, lips, mouth, tongue, or throat, trouble breathing or throat tightness or chest tightness or skin rash, hives etc.
Cautions & Contraindications
Warnings & Precautions
Hypersensitivity: Hypersensitivity reactions such as angioedema have been reported. Discontinue if a clinically significant hypersensitivity reaction occurs.Infections: Deucrava may increase the risk of infection. Avoid use in patients with active or serious infection. If a serious infection develops, discontinue this until the infection resolves.Tuberculosis: Evaluate for TB prior to initiating treatment with Deucrava.Malignancy: Malignancies including lymphomas were observed in clinical trials with Deucrava.Laboratory Abnormalities: Periodically evaluate serum triglycerides. Evaluate liver enzymes at baseline and thereafter in patients with known or suspected liver disease.Immunizations: Avoid use with live vaccines.Potential Risks Related to JAK Inhibition: It is not known whether TYK2 inhibition may be associated with the observed or potential adverse reactions of JAK inhibition. Higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with a JAK inhibitor compared to those treated with TNF blockers in rheumatoid arthritis (RA) patients. This is not approved for use in RA.Rhabdomyolysis and elevated CPK.
Contraindications
Deucravacitinib is contraindicated in patients with a history of hypersensitivity reaction to Deucravacitinib or to any of the excipients of this preparation.